Genome Therapeutics Corp.

Genome Therapeutics, which recently merged with Genesoft Pharmaceuticals, is a biopharmaceutical company committed to the clinical development and commercialization of novel anti-infective therapeutics. The Company is preparing for a launch in the summer of 2004 of its lead product, FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for two indications: community-acquired pneumonia of mild to moderate severity and acute bacterial exacerbations of chronic bronchitis. In addition to an FDA-approved fluoroquinolone antibiotic, the Company also has a novel antibiotic candidate, Ramoplanin, in Phase II and Phase III development for the prevention and treatment of serious hospital-acquired ( www.genomecorp.com )